SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis.


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
09 2020
Historique:
received: 10 03 2020
accepted: 07 05 2020
pubmed: 21 5 2020
medline: 22 6 2021
entrez: 21 5 2020
Statut: epublish

Résumé

To date, there are no network meta-analyses comparing the impact of as-needed treatments in asthma, including the single maintenance and reliever therapy (known as "SMART" or "MART"; for simplicity, SMART will be used hereafter) and the use of inhaled corticosteroid (ICS)/long-acting β

Identifiants

pubmed: 32430423
pii: 13993003.00625-2020
doi: 10.1183/13993003.00625-2020
pii:
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Anti-Asthmatic Agents 0

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright ©ERS 2020.

Déclaration de conflit d'intérêts

Conflict of interest: P. Rogliani reports grants and personal fees from Boehringer Ingelheim, Novartis, Chiesi Farmaceutici and Almirall, personal fees from AstraZeneca, Biofutura, GlaxoSmithKline, Menarini and Mundipharma, grants from Zambon, outside the submitted work. Conflict of interest: B.L. Ritondo has nothing to disclose. Conflict of interest: J. Ora has nothing to disclose. Conflict of interest: M. Cazzola reports grants and personal fees from Boehringer Ingelheim, Novartis, Almirall and Zambon, personal fees from AstraZeneca, Chiesi Farmaceutici, ABC Farmaceutici, Edmond Pharma, Verona Pharma, Ockham Biotech, Biofutura, GlaxoSmithKline, Menarini, Lallemand, Mundipharma and Pfizer, outside the submitted work. Conflict of interest: L. Calzetta reports grants and personal fees from Boehringer Ingelheim, Novartis and Zambon, non-financial support from AstraZeneca, grants from Chiesi Farmaceutici and Almirall, personal fees from ABC Farmaceutici, Edmond Pharma, Verona Pharma and Ockham Biotech, outside the submitted work.

Auteurs

Paola Rogliani (P)

Unit of Respiratory Medicine, Dept of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.
Division of Respiratory Medicine, University Hospital "Tor Vergata", Rome, Italy.

Beatrice Ludovica Ritondo (BL)

Unit of Respiratory Medicine, Dept of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Josuel Ora (J)

Division of Respiratory Medicine, University Hospital "Tor Vergata", Rome, Italy.

Mario Cazzola (M)

Unit of Respiratory Medicine, Dept of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Luigino Calzetta (L)

Unit of Respiratory Medicine, Dept of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH